BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Multicenter randomized double blind study versus placebo during 12 weeks with at first, an
escalating dose period followed by stable dose period at the selected dose.
This double-blind period can be followed by a 9 months open-label period if the patient
wishes to continue with the study product.